POST-POLYCYTHEMIA VERA MYELOFIBROSIS(POST-PV MF)

Clinical trials for POST-POLYCYTHEMIA VERA MYELOFIBROSIS(POST-PV MF) explained in plain language.

Never miss a new study

Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS(POST-PV MF) trials appear

Sign up with your email to follow new studies for POST-POLYCYTHEMIA VERA MYELOFIBROSIS(POST-PV MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

New drug combo tested for rare blood cancer in japan

Disease control Not yet recruiting

This small, early-stage study aims to check if adding a new drug called pelabresib to a standard medication (ruxolitinib) is safe for Japanese adults with myelofibrosis, a rare and serious bone marrow cancer. It will involve about 6 participants who are already taking a stable do…

Matched conditions: POST-POLYCYTHEMIA VERA MYELOFIBROSIS(POST-PV MF)

Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Mar 27, 2026 12:39 UTC

POST-POLYCYTHEMIA VERA MYELOFIBROSIS(POST-PV MF)

Get alerted when new POST-POLYCYTHEMIA VERA MYELOFIBROSIS(POST-PV MF) trials appear

New drug combo tested for rare blood cancer in japan